Palvella Therapeutics PVLA Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Relay Therapeutics, Inc.RLAY

$782K-51.0%

Viridian Therapeutics, Inc.VRDN

$1.86M-20.0%

PrecigenPGEN

$369K-47.7%

Arcutis Biotherapeutics, Inc.ARQT

$182K-78.8%

Ultragenyx PharmaceuticalRARE

$1M-50.0%

Ligand PharmaceuticalsLGND

$1.5M+79.0%

Other financials

Income statement

See full

Revenue$53.0K-97.3%

Operating income-$14.9M-88.7%

Net income-$15.8M-92.6%

EPS (diluted)-$1.20-62.2%

Balance sheet

See full

Cash & equivalents$206.4M+173%

Total debt$584.0K—

Total equity$232.3M+318%

Total assets$263.8M+232%

Cash flow

See full

Operating cash flow-$10.9M-60.5%

CapEx--100%

Free cash flow-$2.7M+72.0%

Valuation

See full

Market cap$1.7B+468%

Enterprise value$1.5B—

P/S41.6×—

Profitability

See full

Operating margin-183.2%-13.5pp

Net margin71.7%+40.4pp

FCF margin-99.8%-34.2pp

Returns & leverage

See full

Return on equity-34.2%—

Debt / equity0×—

Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Palvella Therapeutics's accretion (amortization) of discounts and premiums, investments?: Palvella Therapeutics (PVLA) reported accretion (amortization) of discounts and premiums, investments of $15K in Q1 2026.